MeiraGTx(MGTX)
NEW YORK, NY
BiotechnologyFocus: Gene Therapy
MeiraGTx is a life sciences company focused on Gene Therapy.
Gene Therapy
Funding Stage
PUBLIC
Open Jobs
7
Pipeline & Clinical Trials
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
Radiation-induced XerostomiaClinical Trials (1)
NCT05060341Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia
N/AAAV OPTIRPE65
Leber Congenital Amaurosis (LCA)Clinical Trials (1)
NCT02946879Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
N/AOcular assessments
AchromatopsiaClinical Trials (1)
NCT04124185Natural History Study for Achromatopsia
N/ANatural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
Leber Congenital AmaurosisClinical Trials (1)
NCT02714816Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
N/APrior exposure to AAV-CNGA3 or AAV-CNGB3
AchromatopsiaClinical Trials (1)
NCT03278873Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
N/ANatural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retin
Retinitis PigmentosaAAV2hAQP1
Squamous Cell Head and Neck CancerClinical Trials (1)
NCT02446249Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction
Phase 1AAV2hAQP1: 1 x 10^11 vg/gland
Radiation-Induced Parotid Gland HypofunctionClinical Trials (1)
NCT04043104A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
Phase 1adeno-associated virus vector AAV- CNGA3
AchromatopsiaAAV RPE65
Leber Congenital AmaurosisClinical Trials (1)
NCT02781480Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Phase 1/2AAV-GAD Low Dose
Parkinson's DiseaseClinical Trials (1)
NCT05603312A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants
Phase 1/2AAV5-RPGR
X-Linked Retinitis PigmentosaClinical Trials (1)
NCT03252847Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
Phase 1/2AAV - CNGB3
AchromatopsiaAAV-GAD
Parkinson's DiseaseClinical Trials (1)
NCT05894343Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
Phase 1/2Phase 2
Clinical Trials (1)
NCT06544798Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
Phase 2AAV2-hAQP1 Concentration 1
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsClinical Trials (1)
NCT05926765A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
Phase 2Open Jobs (7)
Calibration & Maintenance Engineer
London
IT1w ago
HR Business Partner, Ireland – 15Mth FTC (Maternity Cover)
Shannon
Human Resources1w ago
Qualified Person - QP
London
Quality Assurance1w ago
QA Operations Team Manager
London
Quality Assurance1w ago
Manager, Data Privacy
London
IT2w ago
Facilities and Maintenance Engineering Technician
London
IT2w ago
QC Validation Specialist
Shannon
Quality Assurance1mo ago
Interview Prep Quick Facts
Portfolio: 13 clinical trials
SEC Filings: 2 available
Open Roles: 7 active jobs
Financials (FY2024)
Revenue
$14M
R&D Spend
$104M(740%)21%
Net Income
-$84MCash
$130MHiring Trend
Stable
7
Open Roles
+2
Added
-0
Filled/Removed
Based on last 4 crawl cycles